Study finds non-hallucinogenic psilocybin neural receptor: A novel target for treating depression and anxiety

Psilocybin—the psychedelic compound that occurs naturally in certain "magic" mushroom species—has been shown in trials to provide long-term treatment for depression and anxiety. But the chemical's ...
Hosted on MSN

Magic Mushrooms Evolved Psilocybin Not Once, but Twice

Researchers don’t know exactly how psilocybin, a psychoactive compound found in psychedelic mushrooms, evolved. Now, a new study adds to the mystery: Its findings reveal that two different groups of ...
Seeking Alpha

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...
Business Insider

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
High Times

Researchers Trace Psilocybin to Dinosaur-Killing Asteroid

A team of researchers at the University of Utah and the Natural History Museum of Utah (NHMU) just completed the largest genomic diversity study for the genus Psilocybe fungi, the psychedelic ...
Benzinga.com

Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression

COMPASS Pathways plc CMPS shared the results from research on the potential of its novel AI technologies to support its proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression (TRD ...